| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | pifithrin-alpha | CTRPv2 | pan-cancer | AAC | -0.067 | 0.08 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | 0.061 | 0.08 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.091 | 0.08 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.065 | 0.08 |
| mRNA | decitabine | CTRPv2 | pan-cancer | AAC | -0.049 | 0.08 |
| mRNA | GSK-J4 | CTRPv2 | pan-cancer | AAC | 0.2 | 0.08 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.1 | 0.08 |
| mRNA | dinaciclib | CTRPv2 | pan-cancer | AAC | 0.085 | 0.08 |
| mRNA | BRD-K61166597 | CTRPv2 | pan-cancer | AAC | -0.055 | 0.09 |
| mRNA | Vorinostat | CTRPv2 | pan-cancer | AAC | 0.057 | 0.09 |